Sign Out
The following undesirable effects have been observed during placebo-controlled clinical trials (n=2344) with the indicated frequencies as follows: (See table.)
Click on icon to see table/diagram/imageIn addition to those events reported during clinical trials, the following side effects have been reported spontaneously during postmarketing use of Fenofibrate. A precise frequency cannot be estimated from the available data and is therefore classified as "not known": Respiratory, thoracic and mediastinal disorders: Interstitial lung disease.
Musculoskeletal, connective tissue and bone disorders: Rhabdomyolysis.
Hepatobiliary disorders: jaundice, complications of cholelithiasis (e.g. cholecystitis, cholangitis, biliary colic).
Skin and Subcutaneous Tissue Disorders: severe cutaneous reactions (e.g. erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis).
Nervous system disorders: Fatigue.
View ADR Monitoring Form
